Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

August 14, 2024

https://www.globenewswire.com/news-release/2024/08/13/2929104/0/en/Cingulate-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Development-Update-on-Major-Milestones-Achieved.html

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025
Licensing Activity Continues

KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended June 30, 2024, and provided a clinical and business update.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.